Summary of minutes of EUCAST Steering Committee Meeting
Brussels, Belgium 21-22 November 2011

Attending
Dr Petra Apfalter PA EUCAST Austria
Dr Derek F.J. Brown DB Scientific Secretary United Kingdom
Dr Rafael Canton RC Clinical Data Co-ordinator Spain
Dr Christian Giske CG SRGA Sweden
Dr Marina Ivanova MI EUCAST Estonia
Prof Gunnar Kahlmeter GK Chairperson Sweden
Prof Alasdair P. MacGowan AM BSAC United Kingdom
Dr Johan W. Mouton JM CRG The Netherlands
Dr Martin Steinbak MS NWGA Norway
Prof Claude-James Soussy CS CA-SFM France
Emanuelle Cambau (present for section 21-22)

Chairman’s welcome

Minutes of meeting of 26-27 September 2011 The minutes were accepted as a correct record.

Matters arising from minutes of 26-27 September 2011 (items not covered by agenda)
In assessing breakpoints for agents with no license the need to keep EMA and EUCAST in line for centrally authorised products was emphasised.

Breakpoints and methods for N. gonorrhoeae will be discussed with the European reference group.

A study of methods for detection of reduced susceptibility of Salmonella spp. to quinolones will be undertaken in December 2011.

New agents A new cephalosporin is still under review. MIC distributions have been received for ceftazidime-avibactam.

EUCAST rationale documents The fosfomycin rationale document will now be completed.

Subcommittees The revised broth microdilution method for yeasts will be released for consultation. Consultations were currently out on breakpoints for posaconazole, itraconazole and amphotericin B.

It was agreed to set up a new subcommittee, “The EUCAST Subcommittee on antimicrobial resistance mechanisms of clinical and/or epidemiological importance”.

Breakpoint issues Comments on breakpoint issues sent for consultation were reviewed and tabulated responses and Steering Committee decisions will be released on the EUCAST website.

1. Remove “uncomplicated” from the UTI restriction on cefditoren for Enterobacteriaceae. Agreed to implement.

2. Remove fosfomycin breakpoints for Pseudomonas spp. Agreed to implement with a note that anecdotal evidence suggests that infections caused by wild type isolates (ECOFF ≤128 mg/L) may be treated with combinations of fosfomycin and other agents.

3. Change vancomycin breakpoints for coagulase-negative staphylococci to S ≤4 mg/L, R >4 mg/L. Agreed to implement although it was accepted that there are good arguments for and against.

4. Restrict the nitrofurantoin breakpoints for Enterococcus spp. to E. faecalis only. Agreed to implement as it is technically correct and affects a small minority of isolates.

5. Replace the “IE” designation with “-” for cefditoren with S. pneumoniae. Agreed to implement.

6. Restrict the phenoxymethylpenicillin breakpoints for group A, C and G streptococci to groups A, C and G only. Agreed to implement the proposed change.

7. Include breakpoints for trimethoprim with group B streptococci for uncomplicated urinary tract infections. Agreed to implement the proposed change.

8. Include breakpoints for levofloxacin and moxifloxacin with viridans group streptococci. Agreed not to implement at present as there is insufficient clarity about indications.

9. Change breakpoints for amoxicillin and amoxicillin-clavulanate with Haemophilus influenzae to S
1. Change breakpoints for chloramphenicol with *H. influenzae* to $S \leq 2\, \text{mg/L}, R > 2\, \text{mg/L}$. Agreed to implement.

10. Change breakpoints for chloramphenicol with *H. influenzae* to $S \leq 2\, \text{mg/L}, R > 2\, \text{mg/L}$. Agreed to implement.

11. Change breakpoints for rifampicin with *H. influenzae* to $S \leq 1\, \text{mg/L}, R > 1\, \text{mg/L}$. Agreed to implement.

12. Remove macrolide breakpoints for *H. influenzae* but include a note on epidemiological cut-off values (ECOFFs) to distinguish wild type from isolates with acquired resistance. Agreed not to implement as agreement was not reached over alternative presentations.

13. Change breakpoints for cefixime for *N. gonorrhoeae* to $S \leq 0.06\, \text{mg/L}, R > 0.06\, \text{mg/L}$. Agreed not to implement as there were significant comments requiring discussion with expert groups.

Agreed to review reporting of benzylpenicillin and *S. pneumoniae* for infections other than meningitis and pneumonia.

Introduction of fluoroquinolones breakpoints for enterococci in UTI are being assessed.

A study of zone diameter breakpoints for nalidixic acid and Enterobacteriaceae in UTI is planned.

Data supporting Pk/Pd breakpoints for colistin are being collected.

Breakpoints based on ECOFFs for topical agents are being discussed.

A note on why there are no systemic breakpoints for most oral cephalosporins is being prepared.

Discussions on benzylpenicillin breakpoints for *N. meningitidis* are continuing.

**Organisms without EUCAST breakpoints** Breakpoints for *L. monocytogenes* are included in v2.0 (January 2012) of the breakpoint tables. Work on *Campylobacter* spp., *Legionella* spp., *Pasteurella multocida*, *Burkholderia cepacia*, *Corynebacterium* spp., *Yersinia enterocolitica*, and *Actinomycetes* spp. is underway. Guidance notes on *Stenotrophomonas maltophilia* are being prepared. Work on *Pseudomonas* spp. other than *P. aeruginosa* is planned for 2012.

**Breakpoint tables** The revised version (2.0) will be released early in December 2011.

**Questionnaire on dosages** A questionnaire for the General Committee is being prepared.

**ESCMID** There will be several EUCAST sessions and activities at the ECCMID in London in 2012.

**EMA** A concept paper on clinical data requirements for evaluation of agents is out for comment.

**CLSI** No new information.

**ECDC** The EUCAST grant contract for the next three years has been signed.

**Implementation of EUCAST breakpoints** Implementation is continuing in many countries.

**EUCAST website** There is now an RSS Newsflow link on the EUCAST front page.

**Steering Committee membership** Two positions available from April 2012 have been advertised.

**Direct susceptibility testing** A guidance document will be released on the EUCAST website.

**Publications** Expert rules version 2.0 are about to be published in CMI. A paper on Pk/Pd in breakpoint setting has been submitted to CMI.

**Presentations of new agents** Preliminary presentations of a new macrolide and a new anti-mycobacterial agent were made to the Steering Committee.

**Any other business** MIC distributions for ampicillin-sulbactam were reviewed. A list of agents recommended for testing is being considered.

**Next meetings** 30-31 January 2012, Lille, France; 3-4 April 2012, London, UK; 9-10 July 2012, Stockholm, Sweden; 24-25 September 2012, Madrid, Spain; 11-13 November 2012, Rome, Italy.

Summary of ratified minutes of meeting 21-22 November 2011. Prepared by DB, GK and RC